No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 5 | 6 | 6 | 6 | 6 | 8 | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | 0 | 1 | 1 | -0 | 0 | -0 | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
CompuMed, Inc. functions as a dedicated provider of advanced telemedicine solutions tailored for organizational clients. The company extends vital clinical care services to both individual patients and various medical facilities internationally. Its primary specializations encompass telecardiology and teleradiology services. These enable healthcare institutions worldwide to connect in real-time with U.S. Board-Certified specialists, utilizing sophisticated cloud-based platforms and integrated medical equipment. Beyond these core areas, CompuMed offers extensive enterprise-level telemedicine frameworks. Its telecardiology portfolio includes a wide array of diagnostic interpretations for adult and pediatric patients, covering examinations such as electrocardiograms (ECG), echocardiograms, vascular studies, holter monitoring, nuclear cardiology assessments, and direct video consultations. In the realm of teleradiology, the company delivers expert image analysis, precise transcription, comprehensive reporting, secure data storage, and video consultations for modalities like Vscan, X-ray, ultrasound, mammography, computed tomography (CT), and magnetic resonance imaging (MRI). CompuMed also offers OsteoGram software, a specialized tool that integrates with both standard and digital X-ray systems to aid in the screening, diagnosis, and ongoing management of osteoporosis. Furthermore, the company supplies mobile ECG and ultrasound solutions, which grant patients direct and immediate access to its network of board-certified medical experts, in addition to providing various medical devices. Its clientele spans a diverse range of sectors, including organ procurement organizations, rural healthcare providers, and correctional healthcare facilities. CompuMed, Inc. was founded in 1973 and is based in Los Angeles, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
CompuMed, Inc. functions as a dedicated provider of advanced telemedicine solutions tailored for organizational clients. The company extends vital clinical care services to both individual patients and various medical facilities internationally. Its primary specializations encompass telecardiology and teleradiology services. These enable healthcare institutions worldwide to connect in real-time with U.S. Board-Certified specialists, utilizing sophisticated cloud-based platforms and integrated medical equipment. Beyond these core areas, CompuMed offers extensive enterprise-level telemedicine frameworks. Its telecardiology portfolio includes a wide array of diagnostic interpretations for adult and pediatric patients, covering examinations such as electrocardiograms (ECG), echocardiograms, vascular studies, holter monitoring, nuclear cardiology assessments, and direct video consultations. In the realm of teleradiology, the company delivers expert image analysis, precise transcription, comprehensive reporting, secure data storage, and video consultations for modalities like Vscan, X-ray, ultrasound, mammography, computed tomography (CT), and magnetic resonance imaging (MRI). CompuMed also offers OsteoGram software, a specialized tool that integrates with both standard and digital X-ray systems to aid in the screening, diagnosis, and ongoing management of osteoporosis. Furthermore, the company supplies mobile ECG and ultrasound solutions, which grant patients direct and immediate access to its network of board-certified medical experts, in addition to providing various medical devices. Its clientele spans a diverse range of sectors, including organ procurement organizations, rural healthcare providers, and correctional healthcare facilities. CompuMed, Inc. was founded in 1973 and is based in Los Angeles, California.